On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) was 1.40% jump from the session before ,before settling in for the closing price of $42.24. A 52-week range for IONS has been $34.32 – $54.44.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 13.97% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -54.34%. With a float of $133.94 million, this company’s outstanding shares have now reached $144.34 million.
In an organization with 927 employees, it is important to assess its efficiency.
Ionis Pharmaceuticals Inc (IONS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Ionis Pharmaceuticals Inc stocks. The insider ownership of Ionis Pharmaceuticals Inc is 8.10%, while institutional ownership is 97.21%. The most recent insider transaction that took place on Feb 16 ’24, was worth 17,219. In this transaction Chief Executive Officer of this company sold 387 shares at a rate of $44.49, taking the stock ownership to the 173,751 shares. Before that another transaction happened on Feb 02 ’24, when Company’s Chief Executive Officer sold 23,501 for $49.37, making the entire transaction worth $1,160,303. This insider now owns 174,138 shares in total.
Ionis Pharmaceuticals Inc (IONS) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/30/2023, it has been observed that the corporation posted -$0.06 earnings per share (EPS) during the time that was better than consensus figure (set at -$0.83) by $0.77. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -54.34% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
You can see what Ionis Pharmaceuticals Inc (IONS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.83. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.56, a number that is poised to hit -1.02 in the next quarter and is forecasted to reach -3.36 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.97 million. That was inferior than the volume of 1.18 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 20.19%. Additionally, its Average True Range was 1.20.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 9.58%, which indicates a significant decrease from 36.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 27.71% in the past 14 days, which was lower than the 32.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $45.56, while its 200-day Moving Average is $45.34. However, in the short run, Ionis Pharmaceuticals Inc’s stock first resistance to watch stands at $43.08. Second resistance stands at $43.33. The third major resistance level sits at $43.62. If the price goes on to break the first support level at $42.54, it is likely to go to the next support level at $42.25. The third support level lies at $42.00 if the price breaches the second support level.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
There are 145,752K outstanding shares of the company, which has a market capitalization of 6.24 billion. As of now, sales total 787,650 K while income totals -366,290 K. Its latest quarter income was 324,500 K while its last quarter net income were -9,260 K.
